IDIOPATHIC PULMONARY FIBROSIS (IPF)

This study tests an oral drug called INS018_055 in 40 adults with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. The main goal is to check the drug's safety over 12 weeks. Participants are randomly assigned to receive the drug or a placebo.

This study tests an experimental inhaled medication called LTI-03 in people with idiopathic pulmonary fibrosis (IPF), a progressive lung-scarring disease. The drug aims to protect lung cells and reduce scarring. About 120 adults aged 40+ with IPF diagnosed within the last 5 years…

This study tests a new drug, SV001, in 48 people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing hard. The main goal is to see if the drug is safe and how the body handles it. Participants will receive either SV001 or a placebo, a…

This study tests a new tablet called HEC585 in about 472 adults aged 40-80 with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Participants are randomly assigned to receive HEC585, a placebo, or an existing drug (pirfenidone) to see …

This study tests an experimental drug called SB17170 in 30 adults aged 40 and older with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and breathing problems. Participants will receive either the drug or a placebo for 12 weeks. The main goal is to see i…

This study looks at the long-term safety of an inhaled medication for people with progressive lung scarring (pulmonary fibrosis). It is for those who already completed an earlier Avalyn Pharma study. The goal is to monitor side effects and lung function over time, not to cure the…

This study tests whether a daily dose of quercetin, a natural compound found in foods like apples and onions, can slow lung scarring and improve breathing in people with pulmonary fibrosis. Researchers will compare 50 patients taking quercetin plus standard care against 50 patien…

This study tests an inhaled version of the drug nintedanib (AP02) in 160 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Participants inhale the drug or a placebo twice daily for 12 weeks. The goal is to see if AP02 improv…

This study tests a new drug called TDI01 for people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing hard. About 508 adults in China will take either TDI01 or a placebo for up to a year. The goal is to see if TDI01 can slow lung fu…

This study tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring and makes breathing hard. About 96 adults aged 40 and older will take BC006 or a placebo for 24 weeks. The goal is to see if BC006 is safe and helps i…

This early-stage study tests an inhaled form of nintedanib (MNKD-201) in 24 adults with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. The main goal is to check safety and how the body processes the drug, not to treat the disease. Participants receive either the dr…

This study collects blood, airway, and urine samples from up to 2,000 healthy volunteers and people with lung diseases like COPD and pulmonary fibrosis. The goal is to establish normal ranges and learn how gene changes in airway cells may lead to disease. Participants must be 18 …

This study looks at how anti-fibrotic medications affect body composition in people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). Researchers will use bioelectrical impedance analysis (BIA) and muscle ultrasound to measure muscle and fat change…

This study looks at lung CT scans from 500 adults with rheumatoid arthritis (RA) to better understand lung problems that can happen with the disease. Researchers want to see which lung patterns are common in RA and how they differ from other lung diseases. Participants will have …

This study tests whether bundling key tests (like CT scans and lung function tests) into a single, coordinated appointment can speed up diagnosis for people with suspected interstitial lung disease. Researchers will compare this streamlined approach to the usual, often fragmented…

This study tests a new way to manage follow-up care for people with interstitial lung disease (ILD). Instead of making multiple trips for tests and doctor visits, patients in the optimized group get everything done in one coordinated hospital visit. The goal is to see if this red…